vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
CROSS COUNTRY HEALTHCARE INC is the larger business by last-quarter revenue ($236.8M vs $196.9M, roughly 1.2× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -23.6%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $16.1M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -21.0%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CCRN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $196.9M |
| Net Profit | $-82.9M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | -30.2% | 1.2% |
| Net Margin | -35.0% | — |
| Revenue YoY | -23.6% | 5.1% |
| Net Profit YoY | -2109.7% | — |
| EPS (diluted) | $-2.56 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | $196.9M | ||
| Q3 25 | $250.1M | $179.5M | ||
| Q2 25 | $274.1M | $181.1M | ||
| Q1 25 | $293.4M | $168.9M | ||
| Q4 24 | $309.9M | $187.3M | ||
| Q3 24 | $315.1M | $168.6M | ||
| Q2 24 | $339.8M | $178.0M | ||
| Q1 24 | $379.2M | $167.1M |
| Q4 25 | $-82.9M | — | ||
| Q3 25 | $-4.8M | $5.4M | ||
| Q2 25 | $-6.7M | $-4.8M | ||
| Q1 25 | $-490.0K | $4.8M | ||
| Q4 24 | $-3.8M | — | ||
| Q3 24 | $2.6M | $-143.5M | ||
| Q2 24 | $-16.1M | $18.9M | ||
| Q1 24 | $2.7M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | 20.4% | 80.9% | ||
| Q2 25 | 20.4% | 77.4% | ||
| Q1 25 | 20.0% | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 20.4% | 76.9% | ||
| Q2 24 | 20.8% | 75.1% | ||
| Q1 24 | 20.4% | 71.6% |
| Q4 25 | -30.2% | 1.2% | ||
| Q3 25 | -2.4% | 3.5% | ||
| Q2 25 | -2.1% | 4.7% | ||
| Q1 25 | -0.3% | 1.2% | ||
| Q4 24 | -1.1% | 13.2% | ||
| Q3 24 | 0.9% | -82.8% | ||
| Q2 24 | -5.7% | 15.9% | ||
| Q1 24 | 0.8% | 7.9% |
| Q4 25 | -35.0% | — | ||
| Q3 25 | -1.9% | 3.0% | ||
| Q2 25 | -2.4% | -2.7% | ||
| Q1 25 | -0.2% | 2.8% | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 0.8% | -85.1% | ||
| Q2 24 | -4.7% | 10.6% | ||
| Q1 24 | 0.7% | 5.4% |
| Q4 25 | $-2.56 | $0.05 | ||
| Q3 25 | $-0.15 | $0.12 | ||
| Q2 25 | $-0.20 | $-0.11 | ||
| Q1 25 | $-0.02 | $0.10 | ||
| Q4 24 | $-0.13 | $0.38 | ||
| Q3 24 | $0.08 | $-3.11 | ||
| Q2 24 | $-0.47 | $0.39 | ||
| Q1 24 | $0.08 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $322.8M | $693.1M |
| Total Assets | $449.0M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | $238.4M | ||
| Q3 25 | $99.1M | $246.3M | ||
| Q2 25 | $81.2M | $445.9M | ||
| Q1 25 | $80.7M | $493.6M | ||
| Q4 24 | $81.6M | $484.6M | ||
| Q3 24 | $64.0M | $453.8M | ||
| Q2 24 | $69.6M | $404.2M | ||
| Q1 24 | $5.2M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $322.8M | $693.1M | ||
| Q3 25 | $408.1M | $727.2M | ||
| Q2 25 | $412.2M | $757.8M | ||
| Q1 25 | $418.2M | $798.5M | ||
| Q4 24 | $419.0M | $778.3M | ||
| Q3 24 | $424.7M | $749.6M | ||
| Q2 24 | $433.3M | $879.3M | ||
| Q1 24 | $462.4M | $892.2M |
| Q4 25 | $449.0M | $1.3B | ||
| Q3 25 | $538.2M | $1.3B | ||
| Q2 25 | $553.8M | $1.5B | ||
| Q1 25 | $576.2M | $1.6B | ||
| Q4 24 | $589.3M | $1.6B | ||
| Q3 24 | $597.4M | $1.5B | ||
| Q2 24 | $602.9M | $1.6B | ||
| Q1 24 | $648.4M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $43.7M |
| Free Cash FlowOCF − Capex | $16.1M | $43.5M |
| FCF MarginFCF / Revenue | 6.8% | 22.1% |
| Capex IntensityCapex / Revenue | 0.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $43.7M | ||
| Q3 25 | $20.1M | $60.8M | ||
| Q2 25 | $4.2M | $12.0M | ||
| Q1 25 | $5.7M | $35.5M | ||
| Q4 24 | $24.2M | $33.1M | ||
| Q3 24 | $7.5M | $53.9M | ||
| Q2 24 | $82.4M | $53.2M | ||
| Q1 24 | $6.0M | $49.1M |
| Q4 25 | $16.1M | $43.5M | ||
| Q3 25 | $17.9M | $57.0M | ||
| Q2 25 | $2.3M | $9.3M | ||
| Q1 25 | $3.8M | $26.9M | ||
| Q4 24 | $21.7M | $31.0M | ||
| Q3 24 | $6.3M | $49.8M | ||
| Q2 24 | $79.6M | $51.6M | ||
| Q1 24 | $3.8M | $46.3M |
| Q4 25 | 6.8% | 22.1% | ||
| Q3 25 | 7.2% | 31.7% | ||
| Q2 25 | 0.8% | 5.1% | ||
| Q1 25 | 1.3% | 15.9% | ||
| Q4 24 | 7.0% | 16.6% | ||
| Q3 24 | 2.0% | 29.6% | ||
| Q2 24 | 23.4% | 29.0% | ||
| Q1 24 | 1.0% | 27.7% |
| Q4 25 | 0.9% | 0.1% | ||
| Q3 25 | 0.9% | 2.2% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.6% | 5.1% | ||
| Q4 24 | 0.8% | 1.1% | ||
| Q3 24 | 0.4% | 2.4% | ||
| Q2 24 | 0.8% | 0.9% | ||
| Q1 24 | 0.6% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | 2.23× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
